Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.58 |
| ▸ | LMNA | P02545 | 3/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | NSD2 | O96028 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.53 |
| ▸ | BRAF | P15056 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.47 |
| ▸ | MAOA | P21397 | 2/20 | 0.46 |
| ▸ | CLK1 | P49759 | 3/20 | 0.46 |
| ▸ | CLK2 | P49760 | 3/20 | 0.46 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1491286 | 0.85 | MAPT (0.56) | MAPTLMNAKDM4EALDH1A1NSD2 | |
| Ethyl Acetate SCHEMBL29093227 | 0.82 | KDM4E (0.47) | MAPTLMNAKDM4EALDH1A1NSD2 | |
| SCHEMBL96458 | 0.81 | KCNA3 (0.54) | MAPTLMNAKDM4EALDH1A1NSD2 | |
| SCHEMBL21917569 | 0.80 | CACNA2D1 (0.50) | MAPTLMNAKDM4EALDH1A1NSD2 | |
| SCHEMBL18356037 | 0.80 | KCNA3 (0.50) | MAPTLMNAKDM4EALDH1A1NSD2 | |
| SCHEMBL11144866 | 0.80 | KCNA3 (0.61) | MAPTLMNAKDM4EALDH1A1NSD2 | |
| SCHEMBL14861116 | 0.80 | KCNA3 (0.65) | MAPTLMNAKDM4EALDH1A1NSD2 | |
| SCHEMBL419729 | 0.79 | KCNA3 (0.53) | MAPTLMNAKDM4EALDH1A1NSD2 | |
| SCHEMBL2974564 | 0.78 | ALDH1A1 (0.60) | MAPTLMNAKDM4EALDH1A1NSD2 | |
| SCHEMBL3994903 | 0.78 | KCNA3 (0.51) | MAPTLMNAKDM4EALDH1A1NSD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 222 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119638622-A | Photocatalytic alkane C (sp)3) Method for activating H bond and constructing C-C bond with aza arene | 中国科学院理化技术研究所 | 2025-03-18 | — | — | CN | disclosed |
| US-20230295114-A1 | AKT3 MODULATORS | Georgiamune Inc. | 2023-09-21 | — | — | US | disclosed |
| CN-110770211-B | Alpha, beta unsaturated amide compound | 协和麒麟株式会社 | 2023-09-19 | — | — | CN | disclosed |
| US-20230225996-A1 | BIOMARKERS OF METAP2 INHIBITORS AND APPLICATIONS THEREOF | SYNDEVRX, INC. | 2023-07-20 | — | — | US | disclosed |
| CN-115286569-B | Method for synthesizing fluoro-aza-aromatic compound through C-H bond functionalization | 南昌大学 | 2023-06-27 | — | — | CN | disclosed |
| CN-108430972-B | Alpha, beta-unsaturated amide compound | 协和麒麟株式会社 | 2022-12-27 | — | — | CN | disclosed |
| CN-115286569-A | Method for synthesizing fluoro-aza-arene compound through C-H bond functionalization | 南昌大学 | 2022-11-04 | — | — | CN | disclosed |
| US-11447471-B2 | α,β-unsaturated amide compound | KYOWA KIRIN CO., LTD. (JP) | 2022-09-20 | — | — | US | disclosed |
| CN-113754631-B | Heteroaryl method of indole | 中国科学院理化技术研究所 | 2022-08-30 | — | — | CN | disclosed |
| US-11332455-B2 | α,β-unsaturated amide compound | KYOWA KIRIN CO., LTD. (JP) | 2022-05-17 | — | — | US | disclosed |
| US-6169093-B1 | FOR TREATMENT OF BENIGN PROSTATIC HYPERPLASIA | PFIZER INC. | 2001-01-02 | — | — | US | disclosed |
| WO-2000064886-A1 | TETRAHYDROISOQUINOLINYL-INDOLE DERIVATIVES FOR THE TREATMENT OF DEPRESSION | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-11-02 | — | — | WO | disclosed |
| EP-0968208-A1 | QUINOLINE AND QUINAZOLINE COMPOUNDS USEFUL IN THERAPY, PARTICULARLY IN THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA | Pfizer Limited (GB) | 2000-01-05 | — | — | EP | disclosed |
| WO-1998030560-A1 | QUINOLINE AND QUINAZOLINE COMPOUNDS USEFUL IN THERAPY, PARTICULARLY IN THE TREATMENT OF BEGNIN PROSTATIC HYPERPLASIA | PFIZER LIMITED (GB) | 1998-07-16 | — | — | WO | disclosed |
| WO-1994027969-A1 | ISOQUINOLINETRIONE DERIVATIVES AS HERBICIDES | ZENECA LIMITED (GB) | 1994-12-08 | — | — | WO | disclosed |
| US-4847264-A | ANTIULCER AGENTS, ANTISECRETORY AGENTS | RORER PHARMACEUTICAL CORPORATION (US) | 1989-07-11 | — | — | US | disclosed |
| US-4632927-A | ANTISECRETORY, ANTIULCER AGENTS | WILLIAM H. RORER, INC. (US) | 1986-12-30 | — | — | US | disclosed |
| EP-0113782-A4 | BICYCLIC NITROGEN HETEROCYCLIC ETHERS AND THIOETHERS, AND THEIR PHARMACEUTICAL USES. | RORER INTERNAT OVERSEAS INC (US) | 1986-03-18 | — | — | EP | disclosed |
| EP-0113782-A1 | BICYCLIC NITROGEN HETEROCYCLIC ETHERS AND THIOETHERS, AND THEIR PHARMACEUTICAL USES | RORER INTERNATIONAL (OVERSEAS) INC. (US) | 1984-07-25 | — | — | EP | disclosed |
| WO-1984000544-A1 | BICYCLIC NITROGEN HETEROCYCLIC ETHERS AND THIOETHERS, AND THEIR PHARMACEUTICAL USES | RORER INT OVERSEAS (US) | 1984-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295114-A1 | AKT3 MODULATORS | AKT3, AKT2, MTOR | MAPT 3962/4885LMNA 1130/4885KDM4E 3961/4885 |
| US-11447471-B2 | α,β-unsaturated amide compound | NR1H2, RXRA, RXRB | MAPT 4590/4885LMNA 1918/4885KDM4E 4037/4885 |
| US-20230225996-A1 | BIOMARKERS OF METAP2 INHIBITORS AND APPLICATIONS THEREOF | METAP2, METAP1, PEBP1 | MAPT 3070/4885LMNA 3649/4885KDM4E 3981/4885 |
| US-11332455-B2 | α,β-unsaturated amide compound | NR1H2, NCOA1, NR0B1 | MAPT 4675/4885LMNA 2043/4885KDM4E 3428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.